REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/13/2026
Back to search
Official data from USPTO
ASEMBIA SPECIALTY PHARMACY SUMMIT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ASEMBIA SPECIALTY PHARMACY SUMMIT
ST13
US500000086972494Class
35, 41
Filing
86972494
Registration
5224350
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
06/14/2026
Trademark type
Word
Nice classes
35, 41
Filing date
04/12/2016
Registration date
06/13/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/11/2024
Last transaction
06/14/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/01/2016
First use in commerce
05/01/2016
Drawing code
4
Owner type
16
Owner location
FLORHAM PARK, NJ, US
Examiner
BODRI, JOHN PETER
Law office
N20
Current location
TMO LAW OFFICE 120
Holders and representatives
Holders
ASEMBIA, LLC
Armada Health Care, LLC
Representatives
Ira Hammer Schenck Price Smith & King LLP
Technical classification
Nice Classes
Class 35Class 41
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Arranging and conducting business conferences for manufacturers and distributors of pharmaceuticalspharmacies
Class 41
Educational servicesconducting conferences in the field of pharmaceuticals for manufacturers and distributors of pharmaceuticalspharmacies
Publications
History of USPTO decisions and trademark events.
29 publications found
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
05/20/2026
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
05/11/2024
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
05/11/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/08/2024
E815
TEAS SECTION 8 & 15 RECEIVED
11/07/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/13/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/18/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
06/13/2017
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/09/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/06/2017
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/20/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/16/2017
IUAF
USE AMENDMENT FILED
04/04/2017
EISU
TEAS STATEMENT OF USE RECEIVED
04/04/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/18/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/23/2016
PUBO
PUBLISHED FOR OPPOSITION
08/23/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/03/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/20/2016
ALIE
ASSIGNED TO LIE
07/18/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/01/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
07/01/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/01/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
07/01/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/01/2016
DOCK
ASSIGNED TO EXAMINER
06/24/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/15/2016
NWAP
NEW APPLICATION ENTERED
04/15/2016
Continuous trademark protection
Get notified about every new filing that threatens ASEMBIA SPECIALTY PHARMACY SUMMIT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.